Elizabeth Smith

Elizabeth Smith

Deputy Director, Regulatory Affairs

Liz Smith provides regulatory guidance to foundation teams and development partners to ensure that regulatory strategies support timely and successful development and registration of products supported by the foundation’s grants.

Before joining the foundation in 2020, Liz spent 28 years providing regulatory guidance and leadership, specializing in biologics, drugs, and cell and gene therapies in both consulting and corporate roles. Most recently, she was an early member of the Juno Therapeutics executive team, first as senior advisor to the CEO and then as senior vice president of regulatory and quality, where she established regulatory strategies for multiple genetically engineered cell therapy assets initially developed at academic institutions (Memorial Sloan Kettering Cancer Center, Fred Hutchinson Cancer Research Center, and Seattle Children’s Research Institute) and then acquired by Juno after Phase I studies. She then served as senior strategic advisor to the company’s development teams and the president of R&D.

Earlier, Liz served as vice president of regulatory affairs at Dendreon, where she expanded the regulatory strategy; chemistry, manufacturing, and controls (CMC); and operations functions and led the regulatory effort to obtain FDA approval of Provenge, the first therapeutic cellular cancer vaccine for the treatment of prostate cancer. Liz also held a variety of regulatory positions at Genentech, with responsibility for the CMC aspects of Herceptin, as well as Immunex (acquired by Amgen), where she began her career in manufacturing.

Liz holds a bachelor’s degree in biology (cum laude) from Central Washington University.

More about the foundation

Our story

Learn about the origins of the foundation and the values that drive our work.

Our work

Learn about where we work around the globe and the programs we've created to address urgent issues in global health, global development, and education.


Read the latest stories, research, and news from across the foundation and subscribe to our weekly newsletter, The Optimist.